(Zip Code)

STAAR SURGICAL CO Form 8-K June 17, 2013		
UNITED STATES		
SECURITIES AND EXCHANGE COM	MISSION	
WASHINGTON, D.C. 20549		
FORM 8-K		
CURRENT REPORT		
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934		
Date of Report (Date of Earliest Event R	eported): June	17, 2013
STAAR Surgical Company		
(Exact name of registrant as specified in its charter)		
Delaware (State or other jurisdiction	0-11634 (Commission	95-3797439 (I.R.S.
of incorporation)	File Number)	Employer Identification No.)
1911 Walker Ave, Monrovia, California		<u>91016</u>

(Address of principal executive offices)

Registrant's telephone number, including area code: 626-303-7902
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On June 17, 2013, STAAR Surgical Company issued a press release announcing that it had received regulatory approvals to market its Visian® Implantable Collamer® Lens (ICLTM) with CentraFLOWTM technology from the KFDA in Korea and the ANMAT in Argentina. A copy of the press release is furnished as Exhibit 99.1 to this Report, and is incorporated herein by this reference.

The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Description

99.1 Press Release dated June 17, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STAAR Surgical Company

June 17, 2013 By:/s/ Barry G. Caldwell Barry G. Caldwell

President and Chief Executive Officer